Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Third-quarter 2009 financial results of Antigenics announced

Third-quarter 2009 financial results of Antigenics announced

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Data from Phase II clinical trial of NKTR-118 presented

Data from Phase II clinical trial of NKTR-118 presented

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

Response Genetics launches new genetic diagnostic test for gastric cancer

Response Genetics launches new genetic diagnostic test for gastric cancer

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

New method found for the treatment of pancreatic cancer

New method found for the treatment of pancreatic cancer

Results of Phase 3 CRYSTAL study of mCRC patients announced

Results of Phase 3 CRYSTAL study of mCRC patients announced

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

Amgen to present its four Phase 3 clinical trial results

Amgen to present its four Phase 3 clinical trial results

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.